Wolverine Asset Management LLC Insmed Inc Put Options Transaction History

Wolverine Asset Management LLC

15 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 13, 2024	SELL	$25.72 - $29.94 $64,300 - $74,850	-2,500 Reduced 36.76%	4,300 $116,000
Q4 2023 Feb 01, 2024	SELL	$23.42 - $31.74 $3.47 Million - $4.7 Million	-148,200 Reduced 95.61%	6,800 $210,000
Q3 2023 Nov 13, 2023	BUY	$19.86 - $26.93 $1.99 Million - $2.7 Million	100,300 Added 183.36%	155,000 $3.91 Million
Q2 2023 Aug 07, 2023	BUY	$16.44 - $21.1 $700,344 - $898,860	42,600 Added 352.07%	54,700 $1.15 Million
Q1 2023 May 08, 2023	SELL	$16.26 - $21.73 $923,568 - $1.23 Million	-56,800 Reduced 82.44%	12,100 $206,000
Q4 2022 Feb 01, 2023	BUY	$16.98 - $23.15 $176,592 - $240,759	10,400 Added 17.78%	68,900 $1.38 Million
Q3 2022 Nov 10, 2022	BUY	$20.88 - $28.21 $1.11 Million - $1.5 Million	53,000 Added 963.64%	58,500 $1.26 Million
Q2 2022 Aug 03, 2022	BUY	$17.07 - $25.71 $66,573 - $100,269	3,900 Added 243.75%	5,500 $108,000
Q4 2021 Feb 09, 2022	BUY	$25.89 - $33.45 $41,424 - $53,520	1,600 New	1,600 $43,000
Q2 2021 Aug 13, 2021	SELL	$24.17 - $36.01 $60,425 - $90,025	-2,500 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$32.28 - $44.3 $616,548 - $846,130	-19,100 Reduced 88.43%	2,500 $85,000
Q4 2020 Feb 12, 2021	BUY	$31.45 - $40.54 $679,320 - $875,664	21,600 New	21,600 $719,000
Q1 2020 May 13, 2020	SELL	$13.63 - $33.98 $680,137 - $1.7 Million	-49,900 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $625,796 - $1.04 Million	40,400 Added 425.26%	49,900 $880,000
Q2 2019 Aug 14, 2019	BUY	$23.0 - $32.19 $218,500 - $305,805	9,500 New	9,500 $243,000

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.